丹麥科研人員不久前發(fā)現(xiàn)一種新的免疫細胞能協(xié)助抵抗癌癥。他們正據(jù)此研制一種新型癌癥疫苗,，目前正在進行臨床試驗。
人體免疫抑制細胞和癌細胞可以產(chǎn)生一種特殊的雙加氧酶,，來抑制免疫細胞的攻擊性,，使其缺乏足夠攻擊力抵抗癌細胞侵襲，甚至還會被癌細胞吞噬,。雙加氧酶的存在使現(xiàn)有癌癥疫苗的有效性大打折扣,。
丹麥海萊烏醫(yī)院癌癥免疫治療中心的研究者在最新一期美國學(xué)術(shù)刊物《血液》上報告說,，他們發(fā)現(xiàn)人體免疫系統(tǒng)中存在一種此前未知的細胞，這種細胞可以殺死那些產(chǎn)生雙加氧酶的細胞,。新發(fā)現(xiàn)的細胞在消滅免疫抑制細胞的同時,，還能直接攻擊癌細胞。
領(lǐng)導(dǎo)這項研究的馬斯·哈爾·安德森說,，研究小組正在研制一種新型癌癥疫苗,，通過增加上述抗癌細胞的數(shù)量，提高機體免疫系統(tǒng)的攻擊力,，從而抵抗癌癥,。海萊烏醫(yī)院正用新疫苗對一些肺癌患者開展臨床試驗，目前的治療效果明顯好于常規(guī)療法,。
研究小組認為,，從原理上說，這種可有效抑制雙加氧酶產(chǎn)生的癌癥疫苗有望與其他療法協(xié)同治療多種癌癥,。（生物谷Bioon.com）
生物谷推薦原文出處：
Blood DOI 10.1182/blood-2010-06-288498
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Rikke B?k S?rensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian Hjorts?, Per thor Straten and Mads Hald Andersen*
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme that is implicated in suppressing T-cell immunity in normal and pathological settings. Here, we describe that spontaneous cytotoxic T-cell reactivity against IDO exists not only in cancer patients but also in healthy individuals. We show that the presence of such IDO-specific CD8+ T cells boosted T-cell immunity against viral or tumor-associated antigens by eliminating IDO+ suppressive cells. This had profound effects on the balance between IL-17-producing CD4+ T cells and regulatory T cells. Furthermore, this caused an increase in the production of the pro-inflammatory cytokines IL-6 and TNF- while decreasing the IL-10 production. Finally, the addition of IDO-inducing agents (i.e. the TLR9 ligand CpG, soluble CTLA4 or IFN-) induced IDO-specific T cells among PBMC from cancer patients as well as healthy donors. In the clinical setting, IDO may serve as an important and widely applicable target for immunotherapeutic strategies where IDO play a significant regulatory role. The present describe for the first time effector T cells with a general regulatory function that may play a vital role for the mounting or maintaining of an effective adaptive immune response. We suggest terming such effector T cells "supporter T cells".
